Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can treated platelets last 5 days? new study finds out

NCT ID NCT06697223

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study looked at whether platelets treated with the INTERCEPT system and stored for 5 days work as well as fresh platelets. 40 healthy adults donated platelets, which were treated and stored, then compared to fresh platelets. The goal was to see how many platelets survived after being given back to the donor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

40 people

The number who actually took part.

Started

Jan 2025

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Normal health status (as determined by the Investigator review of medical history and blood donor physical exam) * Complete blood count (CBC) and serum chemistry values within normal limits or outside of normal reference range but determined by the Investigator, and consultation with the Sponsor, to be not clinically significant. * Meet FDA, AABB or institutional guidelines for allogeneic and plateletpheresis donor qualifications with the following exceptions: o Deferrals due to travel, tattoos/piercings, male to male sexual contact as institutional policies allow * All routine infectious disease testing must be negative or non-reactive (during screening) * Subjects of childbearing potential must agree to use a medically acceptable (as per the Investigator) method of contraception throughout the study * Signed and dated informed consent form Exclusion Criteria: * Clinically significant acute or chronic disease (as determined by the Investigator) * Treatment with aspirin or aspirin-containing medications within 7 days of apheresis or treatment with non-steroidal anti-inflammatory drugs (NSAID), anti-platelet agents or other drugs affecting platelet viability within 3 days of apheresis (e.g., ibuprofen or other NSAIDs) * Subject received platelet inhibitors within 14 days of donation (e.g., clopidogrel, ticlopidine, amphetamines (e.g., Adderall, Dexedrine)) * Immunosuppressive therapy (e.g., oral or IV prednisone) within the past 28 days * Treatment with any medication known to affect platelet viability * Pregnant or nursing females * Received an investigational drug within the past 28 days or current participation in another clinical interventional study * Non study blood component donation throughout the study * Subjects with positive cocaine and/or amphetamine result from urine drug screen * Splenectomized subjects * History of known hypersensitivity to 51Chromium or 111Indium

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy subjects are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • American Red Cross Research Laboratory

    Norfolk, Virginia, 23510, United States

  • Bloodworks Northwest Research Institute

    Seattle, Washington, 98102, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.